Mouries and colleagues reported a reduction in tight junction protein zonulin-1 (ZO-1) and an increase in plasmalemma vesicle-associated protein 1 (PV1), a marker of gut vascular barrier disruption, in HFD-treated mice, highlighting the disruption of these two barriers as an early event in NAFLD-to-NASH progression [22]. Here, TJP1 is linked to metabolic dysfunction-associated steatotic liver disease.